Mizuho Securities Keeps Their Buy Rating on Cytokinetics (CYTK)

Mizuho Securities analyst Salim Syed maintained a Buy rating on Cytokinetics today and set a price target of $118.00.

TipRanks' Prime Week Sale - 70% Off

• Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
• Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Syed covers the Healthcare sector, focusing on stocks such as Century Therapeutics, BridgeBio Pharma, and Amgen. According to TipRanks, Syed has an average return of -1.0% and a 42.91% success rate on recommended stocks.

In addition to Mizuho Securities, Cytokinetics also received a Buy from Citi’s Eric Joseph in a report issued on June 16. However, on the same day, Bank of America Securities maintained a Hold rating on Cytokinetics (NASDAQ: CYTK).

Based on Cytokinetics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $19.36 million and a GAAP net loss of $206.03 million. In comparison, last year the company earned a revenue of $1.58 million and had a GAAP net loss of $161.38 million

Based on the recent corporate insider activity of 155 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CYTK in relation to earlier this year. Earlier this month, Robert Blum, the President & CEO of CYTK sold 7,500.00 shares for a total of $528,450.00.